131 related articles for article (PubMed ID: 38042332)
21. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
Chatterjee C; Kubo K; Pingali V
J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
[TBL] [Abstract][Full Text] [Related]
22. Indication-specific pricing of drugs: a utopian idea, a pragmatic proposition or unrealistic in economically constrained settings?
Meher BR; Padhy BM
Trop Doct; 2020 Apr; 50(2):157-159. PubMed ID: 32036770
[TBL] [Abstract][Full Text] [Related]
23. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
Mendoza RL
J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
[TBL] [Abstract][Full Text] [Related]
24. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
Parmar A; Jiao T; Saluja R; Chan KKW
Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
[TBL] [Abstract][Full Text] [Related]
25. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
Rossini EE; Galeone C; Lucchetti C; Jommi C
Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
[TBL] [Abstract][Full Text] [Related]
26. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
27. Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing Boards.
Bendicksen L; Rome BN; Avorn J; Kesselheim AS
Milbank Q; 2021 Dec; 99(4):1162-1197. PubMed ID: 34375015
[TBL] [Abstract][Full Text] [Related]
28. Estimated Effects of Different Alcohol Taxation and Price Policies on Health Inequalities: A Mathematical Modelling Study.
Meier PS; Holmes J; Angus C; Ally AK; Meng Y; Brennan A
PLoS Med; 2016 Feb; 13(2):e1001963. PubMed ID: 26905063
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
30. Indication-specific pricing of pharmaceuticals in the US healthcare system.
Pearson SD; Dreitlein WB; Henshall C; Towse A
J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
[TBL] [Abstract][Full Text] [Related]
31. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs.
Anderson KE; DiStefano MJ; Liu A; Mattingly TJ; Socal MP; Anderson GF
Value Health; 2023 Sep; 26(9):1381-1388. PubMed ID: 37285915
[TBL] [Abstract][Full Text] [Related]
32. Financial Impact of Alternative Pricing Benchmarks for Physician-Dispensed Drugs in the California Workers' Compensation System.
Wilson L; Turkistani F; Tran DM; Huang W; Lin TK
Appl Health Econ Health Policy; 2019 Apr; 17(2):231-242. PubMed ID: 30484140
[TBL] [Abstract][Full Text] [Related]
33. Does India need a new pharmaceutical policy? Examining the implications of the drug price control order.
Kumar R; Joshi MM; Palod RJ; Dharmagadda S
Int J Health Plann Manage; 2022 Nov; 37(6):3028-3038. PubMed ID: 35983617
[TBL] [Abstract][Full Text] [Related]
34. Inter-Basin Water Transfer Supply Chain Coordination with Ramsey Pricing.
Chen Z; Cheung KCK; Tan M
Int J Environ Res Public Health; 2019 Sep; 16(19):. PubMed ID: 31569400
[TBL] [Abstract][Full Text] [Related]
35. Patents, innovation, and the welfare effects of Medicare Part D.
Gailey A; Lakdawalla D; Sood N
Adv Health Econ Health Serv Res; 2010; 22():317-44. PubMed ID: 20575239
[TBL] [Abstract][Full Text] [Related]
36. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
37. Two ideas to increase innovation and reduce pharmaceutical costs and prices.
Jayadev A; Stiglitz J
Health Aff (Millwood); 2009; 28(1):w165-8. PubMed ID: 19088104
[TBL] [Abstract][Full Text] [Related]
38. Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.
Raimond VC; Feldman WB; Rome BN; Kesselheim AS
Milbank Q; 2021 Mar; 99(1):240-272. PubMed ID: 33751664
[TBL] [Abstract][Full Text] [Related]
39. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
Rand LZ; Kesselheim AS
Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
[TBL] [Abstract][Full Text] [Related]
40. Shining a light in the black box of orphan drug pricing.
Picavet E; Morel T; Cassiman D; Simoens S
Orphanet J Rare Dis; 2014 Apr; 9():62. PubMed ID: 24767472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
